| Name | Title | Contact Details |
|---|
Western Drug Medical Supply is a Glendale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sophono is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliance Pharma is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
NeoChord is a venture backed medical device company that has developed a proprietary device which allows mitral valve repair to be performed on a beating heart through a 2- to 3-inch incision between the ribs in patients with severe mitral valve regurgitation (MR). In contrast, most mitral valve repair procedures are performed through a 3 to 10 inch chest incision (sternotomy) that involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on cardio-pulmonary bypass (CPB).